Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Leases (2019 - 2025)

Historic Capital Leases for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $1.8 million.

  • Kymera Therapeutics' Capital Leases rose 344.04% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 344.04%. This contributed to the annual value of $2.2 million for FY2024, which is 7109.92% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Capital Leases of $1.8 million as of Q3 2025, which was up 344.04% from $2.2 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Capital Leases high stood at $2.2 million for Q4 2024, and its period low was $498000.0 during Q1 2021.
  • For the 5-year period, Kymera Therapeutics' Capital Leases averaged around $1.2 million, with its median value being $1.1 million (2021).
  • As far as peak fluctuations go, Kymera Therapeutics' Capital Leases crashed by 4877.51% in 2022, and later surged by 17122.86% in 2024.
  • Kymera Therapeutics' Capital Leases (Quarter) stood at $1.1 million in 2021, then increased by 9.3% to $1.2 million in 2022, then rose by 4.41% to $1.3 million in 2023, then skyrocketed by 71.1% to $2.2 million in 2024, then decreased by 18.96% to $1.8 million in 2025.
  • Its Capital Leases was $1.8 million in Q3 2025, compared to $2.2 million in Q2 2025 and $1.9 million in Q1 2025.